Galcanezumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | calcitonin |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 1578199-75-3 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6392H9854N1686O2018S46 |
| Molar mass | 144.1 kDa |
Galcanezumab (INN) is a humanized monoclonal antibody designed for the prevention of migraine.[1][2]
This drug was developed by Eli Lilly & Co.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Galcanezumab, American Medical Association.
- ↑ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
This article is issued from Wikipedia - version of the 11/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.